iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,230.00
-70.00 (-1.63%)
Apr 24, 2025, 2:37 PM KST
-38.52%
Market Cap 135.94B
Revenue (ttm) 6.42B
Net Income (ttm) -2.59B
Shares Out 31.61M
EPS (ttm) -78.75
PE Ratio n/a
Forward PE n/a
Dividend 100.00 (2.40%)
Ex-Dividend Date Dec 27, 2024
Volume 54,792
Average Volume 104,720
Open 4,290.00
Previous Close 4,300.00
Day's Range 4,180.00 - 4,310.00
52-Week Range 3,350.00 - 7,110.00
Beta 0.64
RSI 63.80
Earnings Date May 13, 2025

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 76
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2024, iNtRON Biotechnology's revenue was 6.42 billion, a decrease of -33.05% compared to the previous year's 9.59 billion. Losses were -2.59 billion, -73.27% less than in 2023.

Financial Statements

News

There is no news available yet.